

---

# Table of Contents

---

Publisher's Note ..... I  
Foreword ..... II  
Contributing Authors ..... III

## Chapter 1

**The Problem and the Challenge** ..... 3  
Jeremiah Stamler, M.D.; James A. Schoenberger, M.D.;  
Richard B. Shekelle, Ph.D.; and Rose Stamler, M.A.

Prevalence in the United States by Age, Sex, and Race ..... 3  
Morbidity, Disability, and Mortality due to Hypertensive  
Disease ..... 5  
Mortality Statistics Tell Only Part of the Story ..... 11  
Correlates of Hypertensive Disease ..... 11  
Family history ..... 11  
"Spiking" in youth ..... 12  
Obesity/Salt ..... 13  
Cigarette smoking ..... 15  
Hypercholesterolemia/Hyperglycemia ..... 15  
Effectiveness of Antihypertensive Medication ..... 15  
Diagnostic and Therapeutic Status of Hypertensive Persons  
in the United States ..... 18  
Programmatic Proposals for the Control of Hypertension .... 23  
The Financial and Social Soundness of the Effort to  
Control Hypertension ..... 27

## Chapter 2

|                                  |    |
|----------------------------------|----|
| <b>A Time for Action</b> .....   | 35 |
| Theodore Cooper, M.D., Ph.D.     |    |
| Critical Mass of Knowledge ..... | 36 |
| Mobilizing Resources .....       | 36 |
| Public Awareness Efforts .....   | 37 |
| Screening Efforts .....          | 38 |
| The Community Role .....         | 38 |
| The Need for Innovation .....    | 39 |
| Conclusion .....                 | 39 |

## Chapter 3

|                                                                            |    |
|----------------------------------------------------------------------------|----|
| <b>A Functional Approach to Screening</b> .....                            | 43 |
| Morton H. Maxwell, M.D.                                                    |    |
| How to Find the Hypertensives .....                                        | 43 |
| Hypertension must be taken more seriously .....                            | 43 |
| Is widespread community screening the answer? .....                        | 44 |
| How can the present system cope with the problem? .....                    | 46 |
| The Technique of Blood Pressure Measurement .....                          | 47 |
| <b>The Korotkoff Sounds</b> .....                                          | 48 |
| Criteria for systolic and diastolic blood pressures .....                  | 49 |
| Measuring the blood pressure .....                                         | 50 |
| Errors in techniques and variations of blood pressure .....                | 50 |
| Some Factors That Influence Blood Pressure .....                           | 51 |
| Blood Pressure: When Should It Be Labeled "High"? .....                    | 53 |
| The Training of Medical and Paramedical Personnel .....                    | 55 |
| Improving the conditions of blood pressure measurement ...                 | 55 |
| Improving the accuracy of blood pressure measurement ...                   | 56 |
| Hearing acuity .....                                                       | 57 |
| Observer bias .....                                                        | 57 |
| Terminal digit preference .....                                            | 57 |
| Differences in mental concentration and reaction time ...                  | 57 |
| Rates of inflation and deflation and proper placement<br>of the cuff ..... | 59 |
| The Training Program .....                                                 | 59 |
| Conclusions .....                                                          | 60 |

## Chapter 4

### **Current Views on Diagnostic Evaluation** . . . . . 67

Ray W. Gifford, Jr., M.D.

|                                                       |    |
|-------------------------------------------------------|----|
| History and Physical Examination . . . . .            | 68 |
| History . . . . .                                     | 69 |
| Physical examination . . . . .                        | 70 |
| Blood pressure measurement . . . . .                  | 70 |
| Optic fundus . . . . .                                | 71 |
| Cardiac examination . . . . .                         | 72 |
| Examination of the peripheral arteries . . . . .      | 72 |
| Neurologic examination . . . . .                      | 73 |
| Abdominal examination . . . . .                       | 73 |
| General observations . . . . .                        | 73 |
| Laboratory and Roentgenographic Examination . . . . . | 74 |
| The Search for Curable Causes . . . . .               | 74 |
| Pheochromocytoma . . . . .                            | 75 |
| Renovascular hypertension . . . . .                   | 75 |
| Primary aldosteronism . . . . .                       | 77 |
| Coarctation of the aorta . . . . .                    | 78 |
| Cushing's syndrome . . . . .                          | 78 |
| Hypertension and Renal Parenchymal Disease . . . . .  | 78 |
| Summary . . . . .                                     | 79 |

## Chapter 5

### **A Practical Guide to Medical Management** . . . . . 83

Ray W. Gifford, Jr., M.D.

|                                     |    |
|-------------------------------------|----|
| I. ESSENTIAL HYPERTENSION . . . . . | 83 |
| Whom to Treat . . . . .             | 83 |
| When to Treat . . . . .             | 85 |
| Ancillary Measures . . . . .        | 85 |
| Sedation . . . . .                  | 86 |
| Diet . . . . .                      | 86 |
| Rest . . . . .                      | 87 |
| Exercise . . . . .                  | 87 |
| Tobacco . . . . .                   | 87 |

## Chapter 5 (continued)

|                                                          |     |
|----------------------------------------------------------|-----|
| Objectives of Therapy                                    | 87  |
| Antihypertensive Drugs                                   | 87  |
| Oral diuretics                                           | 88  |
| Vasodilators                                             | 91  |
| Sympathetic inhibiting agents                            | 92  |
| Rauwolfia compounds                                      | 92  |
| Ganglion blocking agents                                 | 93  |
| Selective sympathetic inhibitor                          | 93  |
| False neurotransmitters                                  | 96  |
| Methyldopa                                               | 96  |
| Pargyline                                                | 97  |
| Sympathetic receptor blockade                            | 98  |
| Beta blockade                                            | 98  |
| Alpha blockade                                           | 98  |
| Choice of Drug Regimens                                  | 99  |
| Uncomplicated hypertension                               | 99  |
| Complicated hypertension                                 | 100 |
| Congestive heart failure                                 | 100 |
| Azotemia                                                 | 101 |
| Coronary and cerebral atherosclerosis                    | 101 |
| Labile hypertension                                      | 102 |
| Systolic hypertension                                    | 102 |
| Side effects                                             | 103 |
| Some Secrets to Success in the Treatment of Hypertension | 103 |
| <br>                                                     |     |
| II. HYPERTENSIVE CRISES                                  | 104 |
| Route of Parenteral Administration                       | 105 |
| Antihypertensive Drugs for Parenteral Administration     | 107 |
| Hydralazine                                              | 107 |
| Diazoxide                                                | 107 |
| Sodium nitroprusside                                     | 108 |
| Reserpine                                                | 108 |
| Ganglion blocking agents                                 | 110 |
| Methyldopa                                               | 110 |
| Phentolamine                                             | 110 |
| The Role of Oral Antihypertensive Drugs                  | 111 |

## Chapter 6

### **New Techniques for Improving Patient Compliance . . . . . 117**

Frank A. Finnerty, Jr., M.D.

|                                           |     |
|-------------------------------------------|-----|
| A Brief Overview of the Problem . . . . . | 117 |
| Recording Problems . . . . .              | 117 |
| Treatment Problems . . . . .              | 118 |
| Patient Problems . . . . .                | 119 |
| Researching the Patient Problem . . . . . | 120 |
| Applying the Research Results . . . . .   | 120 |
| First visit . . . . .                     | 121 |
| Second visit . . . . .                    | 121 |
| Later visits . . . . .                    | 121 |
| Our Experience . . . . .                  | 122 |
| Conclusion . . . . .                      | 124 |

### **Appendix . . . . . 127**

#### **I. BLOOD PRESSURE MEASUREMENT AIDS . . . . . 129**

|                                                                                       |     |
|---------------------------------------------------------------------------------------|-----|
| First Visit Interview Form . . . . .                                                  | 130 |
| Procedures and Instructions for Taking Patient's Initial<br>Medical History . . . . . | 139 |
| Measuring Your Blood Pressure . . . . .                                               | 147 |

#### **II. LANDMARK STUDIES . . . . . 151**

|                                                                                                                                                                                                                                        |     |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| Veterans Administration Cooperative Study Group<br>on Antihypertensive Agents: Effects of Treatment<br>on Morbidity in Hypertension<br>Results in Patients With Diastolic Blood Pressures<br>Averaging 115 Through 129 mm Hg . . . . . | 153 |
| Results in Patients With Diastolic Blood Pressure<br>Averaging 90 Through 114 mm Hg . . . . .                                                                                                                                          | 161 |
| Influence of Age, Diastolic Pressure, and Prior Cardio-<br>vascular Disease; Further Analysis of Side Effects . .                                                                                                                      | 173 |
| The Framingham Study<br>"Epideimiologic Assessment of the Role of Blood<br>Pressure in Stroke" . . . . .                                                                                                                               | 189 |
| "Role of Blood Pressure in the Development of<br>Congestive Heart Failure" . . . . .                                                                                                                                                   | 201 |

Report of Inter-Society Commission for Heart Disease  
Resources  
Guidelines for the detection, diagnosis and manage-  
ment of hypertensive populations . . . . . 209

III. RESOURCES . . . . . 221  
Major sources of hypertension materials . . . . . 223  
Lay materials on hypertension . . . . . 224  
Professional materials on hypertension . . . . . 227  
Miscellaneous resources . . . . . 231

Subject Index . . . . . 235